Full Press Release Details
Precision Oncology Through Synthetic Lethality May 2022
Precision Oncology Through Synthetic Lethality May 2022
APRE
Precision Oncology Through Synthetic Lethality May 2022 Forward - Looking Statements Certain information contained in this presentation includes " forward - looking statements " , within the meaning of Section 27 A of th
Key Takeaway: Precision Oncology Through Synthetic Lethality May 2022
Precision Oncology Through Synthetic Lethality May 2022
Price reaction · baseline $19.256 (2022-05-16 close) · hit after-hours · clean, no other APRE news in the window
day 0 close
-29.7%
day 1 · peak
-35.1%
day 3
-31.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+51%
120-day peak, hindsight
Typical move
5.9%
average across 7 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
APR-246+ azacitidine
Phase 3 · MDS